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Genetic intratumour heterogeneity (ITH) has long been observed in
a variety of cancers, but its extent at the level of the single cell and single
nucleotide is only now becoming apparent with the use of next genera-
tion sequencing technologies (reviewed in [1,2]). Branched tumour
evolution gives rise to multiple genetically distinct subclones which
may co-exist in the tumour mass and produce varying degrees of ITH
[3]. A recent study in colorectal cancer shows that most detectable ITH
occurs early after the transition to an advanced tumour as a result of
fairly neutral subclonal evolution [4]. Critically, when heterogeneous
tumours are sampled via a single biopsy the true extent of ITH is
underestimated [5]. Intra-tumour diversity has rightly been perceived
as a signiﬁcant problem, but on the plus side, by informing phylogenetic
analyses it can help to reconstruct tumour histories and estimate muta-
tional timing (Fig. 1).
Clonal mutations (also termed: ubiquitous, shared or foundermuta-
tions) are present in all the malignant cells under examination and are
placed on the trunk of the phylogenetic trees (Fig. 1: truncalmutations).
The most-recent common ancestor, whichmay no longer be detectable
in the population which is sampled, is characterised by mutations that
are fully clonal. Subclonal mutations are present in a proportion of
themalignant cells under examination andmap to the branches of phy-
logenetic trees (Fig. 1: branch mutations). Subclonal populations, or
subclones, are characterised by the presence of at least one subclonal
mutation. In a phylogenetic tree the distance between a subclone and
the most-recent common ancestor indicates the degree of their rela-
tionship (Fig. 1) and provides an approximation of mutational timing:
trunk mutations occur prior to branch mutations. In what regard isClone
Mutations
A B C D E F
C1
C2
C3
C4
C5
A,B
C
F
D
D
GL
C1
C2
C4
C3
Fig. 1.An example of phylogenetic inference. The table indicates ﬁve clones C1–C5which are ch
at the germline (GL). Mutations acquired by particular clones are indicated. Branch and trunk le
which in this case is either 1 or 2. It is assumed that mutations cannot be lost which is why C4this information meaningful or useful? At the most basic level the
knowledge of mutational timing can illuminate the critical steps in
tumourigenesis and identify mutational events linked to tumour initia-
tion, maintenance and progression and resolve the timing of speciﬁc
mutational or genomic instability processes during tumour evolution.
Next, mutational timing can help distinguish driver and passenger
mutations. Recent analyses suggest that half ormore of the somaticmu-
tations in tumours of self-renewing tissues occur before malignant
transformation [6]. By identifying mutations in pre-malignant, or in-
situ lesions, a signiﬁcant number of candidate driver mutations can be
eliminated. For example, in a genome-wide analysis of progression
from Barrett's oesophagus to invasive oesophageal adenocarcinoma,
themajority of mutations accumulated early, prior to tumour initiation,
and only two mutations were linked to progression from the pre-
malignant to malignant state [7]. However useful, these strategies are
only applicable in tumour types where early lesions can be readily iden-
tiﬁed and sampled.
The knowledge ofmutational timinghas a potential clinical utility. In
clear cell renal cell carcinoma (ccRCC) clonal events are very consistent
(VHL, loss of 3p) [8] and yet the patient outcomes are diverse, suggest-
ing that late/subclonal events inﬂuence the disease course. Consistent
with this, the presence of subclones has been linked to poor clinical
outcome in chronic lymphocytic leukaemia (CLL) [9], disease relapse
in lung adenocarcinoma [10] and to increased risk of progression to
malignancy in Barrett's oesophagus [11]. The order in which JAK2 and
TET2 mutations are acquired can inﬂuence clinical features, response
to therapy and clonal evolution in myeloproliferative neoplasms [12].
Although the within-tumour clonal dynamics can be effectively-
neutral in some cancer types [4,13] selective bottlenecks will occur, E
C5
Terminal branch
Internal branch
Trunk
aracterised by the presence or the absence of mutations A, B, C, D, E, and F. Trees are rooted
ngths are proportional to the number of mutations on the corresponding branch or trunk,
is derived from C1 and not C2 or C3.
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critical for prediction of therapeutic response. Early/clonal events are
appealing therapeutic targets as they characterise the entire tumour
population. Conversely, when subclonal mutations are targeted on
their own, a suboptimal or even an adverse outcome can be expected.
For example, BRAFmutations are frequently subclonal in multiple mye-
loma [14–17]. Treatment of BRAF wild-type myeloma cells with BRAF
inhibitors caused paradoxical activation of the mitogen-activated pro-
tein kinase (MAPK) pathway, and this effect was further exaggerated
in the presence of concurrent mutations in NRAS or KRAS[14]. Subclonal
mutations in NRAS account for BRAF-inhibitor resistance in BRAF-
mutant melanoma [18], and furthermore, BRAF inhibitors can induce
metastases in RAS-mutant melanoma cells [19]. In patients with occult
RAS-mutant cancers BRAF inhibitors have been reported to potentiate
tumourigenesis (including RAS-mutant skin tumours, RAS-mutant
leukaemia, and metastatic recurrence of RAS-mutant colorectal cancer)
[20]. Subclonal ampliﬁcation ofMET and secondary EGFRmutations are
linked to acquired resistance to EGFR inhibitors in EGFR-mutant lung
cancer [21]. Thus, subclonal events can predict the mechanism of resis-
tance to therapies that solely target the truncal driver mutation. An
improved understanding of mutational timing could aid the design of
combined therapeutic approaches or second line therapies. Finally, the
view that truncal events are the most important therapeutic targets
may be too simplistic. There is evidence that subclones can drive tu-
mours by inducing tumour-promoting microenvironmental changes
[22] and enhancing the tumourgenicity of the tumour as a whole
[23]. Such subclones could provide additional targets for therapeutic
intervention.
Mutational chronology is also relevant to our understanding of me-
tastases and selective bottlenecks are again expected in this context
due to differing environmental conditions between the primary and
metastatic sites, and between metastatic sites. There is evidence that
subclonal lineages become enriched in themetastases [24] and that dif-
ferent subclones in the primary give rise to inter-metastatic heteroge-
neity [25]. Analysis of four spatially separate metastases in two
melanoma cases highlighted the genetic alterations responsible for dif-
ferential drug resistance among metastatic tumours [26]. Thus, some
subclones which occur later in tumour evolution could predict the com-
position of the metastases and reveal metastases-associated mutations.
Inferring mutational timing across the genomic landscape of a can-
cer can also estimate tumour age [27,28]. This knowledge could inform
optimal cancer screening strategies by highlighting the window of
opportunity for screening. Measures of clonal diversity can predict
progression of Barrett's oesophagus to a full-blown adenocarcinoma
[11]. The same group have reported that clonal diversity is modulated
by the use of non-steroidal anti-inﬂammatories [29], suggesting a
potential mechanism of chemoprevention by aspirin.
Despite these critical notions, to date, fairly limited evolutionary per-
spective featured in the research of cancer progression and treatment
resistance. A recent study reported that of almost 7000 papers on ther-
apeutic resistance and/or relapse in cancers only 1% had evolutionary
terms in their abstracts [30]. Thus, the study of tumour evolution and
mutational timing is an unrealised opportunity for advances in cancer
research [30]. In this reviewwe focus on recent strategies to infer muta-
tional timing fromnext generation sequencing data, with a special focus
on mutations in known driver genes.
2. Sampling methods
2.1. Paired samples
Most genomic datasets contain single data points from multiple in-
dividuals, but mutational timing can be inferred with greater accuracy
from multiple either spatially or temporally separate samples from the
same individual (Fig. 2A&B). To date, such studies have generally used
manual curation to reconstruct phylogenetic trees. Mutational timingis inferred on the basis of mutations being shared (early events) or
private (later events). Phylogenies are further resolved by incorporating
computationally-estimated variant allele frequencies (VAFs), combined
with local copy number states and estimations of tumour purity to iden-
tify sets of mutations whose VAFs shift together over time.
Spatial or geographical heterogeneity has been explored though
multi-regional sampling of primary and/ormetastatic tumours. This ap-
proach has been applied to a small number of tumour types including
ccRCC [5,31], glioblastoma [32] lung adenocarcinoma [10,27] and breast
cancer [33]. In ccRCC, drivermutationsmapmostly to the brancheswith
only one or two driver mutations occurring on the trunk. By compari-
son, in glioblastoma more driver mutations mapped to the trunk, and
in the two studies of lung adenocarcinoma, the majority of known
driver mutations were classed as early events. These results should be
interpreted with caution however, as our knowledge of driver genes is
biased by frequent detection of events which are consistently clonal
and detected at high frequency in single biopsy samples.
Studies of temporally separated samples have included matched
primary-metastasis pairs [25,26,28,34–43], primary tumour and re-
lapsed pairs [17,44,45] or serial tumour sampling [9,15,41,42]. These
studies have shown that subclonal driver mutations anticipate the
dominant genetic composition of the relapsing tumour in CLL [9]; that
multiple subclones contribute to metastases in pancreatic cancer,
prostate cancer and melanoma [26,28,46], and that phylogenetic trees
across metastases can show organ-speciﬁc branches [25]. Conversely,
in a single case report ccRCC metastases appeared to be monoclonal
[38]. Some studies of matched primary-metastasis pairs found evidence
of de novomutations in themetastases [28,34,37,41,43]. Suchmutations
are either very late events and indicate ongoing tumour evolution in
metastatic sites, or are present in minor subclones of the primary tu-
mour which evaded detection (Fig. 2A). Recently, longitudinal studies
have included post-mortem sampling of spatially separate metastases
[47], an approach that promises to yield a highly accurate portrayal of
cancers' evolution and mutational timing.
Employing these labour-intensive, technically challenging sampling
techniques still does not resolve clonal structures in full as illustrated by
the ﬁnding of intraregional subclonal populations [10]. Even very small
regional biopsy samples contain an admixture of cells, which require
deconvoluting. Further, the accuracy of clonal inferences is dependent
on sequencing coverage, tumour purity and local copy number dynam-
ics; inadequate depth of sequencing can mis-categorise shared muta-
tions as private or ubiquitous [10]. Lastly, even multi-region sampling
of a tumour represents a relatively small proportion of the overall
tumour volume and could ignore signiﬁcant clonal dynamics.
Ultimately, sequencing single cells or single tumour nuclei is the
least biased approach to assessing heterogeneity within a tumour [48].
Single-cell genomic studies have been reported in a number of tumour
types [49–53] revealing detailed clonal evolution and marked inter-
cellular heterogeneity. Whilst promising, these technologies still
require optimisation and presently they are not high throughput or
widely available, nor can they be considered exhaustive approaches
to deﬁne tumour phylogenies. In the future their use may become
routine, but bulk sequencing will remain the basis of cancer evolu-
tion studies for the time being.
2.2. Single samples
Most genomic studies involve only single samples representing indi-
vidual tumours. In these unfractionated samples mutational timing
must be inferred from the frequency of eachmutation in the population.
Clonal/early mutations are supported by high VAFs and subclonal/late
mutations by low VAFs. Taking into account tumour purity and local
copy number, mutations with similar VAFs are clustered together into
(sub)clones. In addition to SNVs and small insertions and deletion
most studies consider copy number alterations (CNAs), although this
is complicated by the absence of a digital readout for CNAs (in contrast
A Multi-regional sequencing
B Matched pair sequencing
Relapse/ metastatic/ 
treatment-resistant tumourPrimary tumour
C Single sample sequencing
D Single cell/nucleus sequencing 
Fig. 2.Dissecting intratumour heterogeneity using different sampling approaches. Each colour represents a distinct subclone in the tumourmass. A. In this casemulti-regional sequencing
picks up the blue, orange and red clones aswell as amixture of blue and dark green clones. The light green clone ismissed. B. Single biopsy of the primary tumour picks up amixture of blue
and light green clones. Paired sample shows clonal expansion of the light green clone. C. Single biopsy approach picks up a mixture of blue and orange clones only. D. All the clones are
picked up by single cell sequencing.
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proach. First, the VAF of a givenmutation is a composite measure of the
proportion of tumour cells that harbour themutation, the proportion of
“normal” cells in the sample, and the number of allelic copies of themu-
tation in each cell. These factors can be partly deconvolved, but not
completely resolved in bulk sequencing experiments. Second, it has
been noted that single biopsy studies can misclassify subclonal muta-
tions as clonal giving an illusion of clonal dominance [31]. Third, as se-
quencing reads are short, VAFs of different mutations have to be
measured independently. Mutations with similar VAFs are assumed to
co-occur within the same cells, but this may not be the case. Similarly,
whilst it is assumed that clones at higher frequencies give rise to the
clones with lower frequencies, subclones with overlapping VAFs cannot
be distinguished [55]. Lastly, mostmutational calling algorithms are not
designed to uncover low frequency events, and so late-occurringmuta-
tions may be missed. Approaches such as MuTect [56], developed with
the aim of detecting low-allele fractions represent a substantialadvance, but in the absence of repeat or parallel sampling subclonal ar-
chitecture will remain incompletely resolved.
A more general strategy to infer mutational timing, originally
described by Pleasance et al. [57] is combining mutational data with
chromosome or whole genome duplication events: mutations which
precede chromosomal duplication show higher copy number than
those occurring after duplication [58,59].
3. Computational methods
Various computational methods aimed at resolving clonal architec-
tures have been published in recent years (for an in-depth review see,
Beerenwinkel et al. 2015 [60]). The majority of methods seek to
deconvolve the number of clonal and subclonal clusters. This problem
is suited to a ﬂexible Bayesian analysis, as mutations will be derived
from an unknown number of subclones, present at unknown cancer
cell fraction, and representing an unknown proportion of the entire
268 S. Turajlic et al. / Biochimica et Biophysica Acta 1855 (2015) 264–275mutational catalogue [61]. Based on the identiﬁed SNV clusters, phylo-
genetic tree reconstruction can be performed. Most approaches make
the assumption that the samemutation only occurs once in the process
of a tumour's evolution and that nomutation can be lost. In the analysis
of single samples there are often multiple trees which can ﬁt the given
pattern of VAFs, and few topological constraints exist to limit the
space of solutions [60]. The advantage of analysing paired samples is
that they contain different sets of VAFs and this can constrain the evolu-
tion space.
Below we describe published approaches to clonal inference and
phylogenetic tree reconstruction based on single nucleotide variant
(SNV) and allele speciﬁc copy number calls in single and multiple
matched tumour samples
3.1. PyClone
PyClone [62] pioneered the integration of VAFs with allele speciﬁc
copy number and purity estimates in order to deﬁne the subclonal com-
position of individual biopsies. The method was ﬁrst applied to 104 tri-
ple negative breast cancers, shedding light onmutation timing of driver
genes in these cancers (see below). Pyclone uses a Bayesian Dirichlet
clustering process to jointly group deeply sequenced (N1000×) muta-
tions and infer posterior density estimates over the cancer cell fraction
(CCF) for each mutation. A limitation of this approach, however, is
that it assumes all copy number events are clonal.
3.2. SciClone
SciClone [54] also applies a Bayesian clustering method to single or
paired (spatially or temporally separate) samples to infer the subclonal
composition of a tumour. A deﬁning feature of SciClone's approach is
that it focuses exclusively on SNV variants in copy-number neutral,
loss of heterozygosity (LOH)-free portions of the genome. Although
this feature circumvents issues associated with clonal and subclonal
copy number aberrations it means that not all mutations can be associ-
ated with SNV clusters. Nevertheless, several studies using SciClone
have been published to date [26,63], revealing subclonal structures in
melanoma and leukaemia.
3.3. CloneHD
CloneHD [64] performs subclone reconstruction from either individ-
ual or integrated analysis of two types of data: copy number (derived
from read depth and B-allele fraction in germline samples) and somatic
SNVs using Hidden Markov Models. The algorithm can be applied to
single as well as longitudinal or multiregional samples. Using CloneHD
the authors deciphered clonal progression in CLL using WGS data
alone [42],whilst still recovering an evolutionary history aswas inferred
by targeted deep sequencing in this study.
3.4. PhyloSub
PhyloSub [65] represents an extension of previous approaches in
that it both clusters SNVs and performs phylogenetic tree inferences.
In the case of multiple phylogenies being consistent with a given set
of SNV frequencies, it represents the uncertainty in the tumour phylog-
eny using a “partial order plot”. As with other approaches PhyloSub's
ability to identify subclones depends on their overall frequency in the
population, the number of SNVs that deﬁne it, and the accuracy of the
VAF estimate (which is in turn dependent on sequencing depth and
accuracy of the copy number estimate). The authors apply the PhyloSub
to a real dataset [42] and produce a good agreement with the semi-
manually curated phylogenies in the published study. PhyloSub has
recently been extended to include copy number aberrations and WGS
data (PhyloWGS).3.5. TrAp
TrAp [66] also attempts to deﬁne the evolutionary history of
tumours. The method uses exome sequencing data and is speciﬁcally
designed to deconvolute a single aggregate signal into its subclonal
components. The authors' inference of the clonal evolution of AML
cases using the TrAp algorithm was in agreement with that inferred
by Ding et al. [44].
3.6. SubcloneSeeker
Based on identiﬁed SNV clusters, SubcloneSeeker [67] focuses on
phylogenetic reconstruction. Speciﬁcally, SubcloneSeeker seeks to enu-
merate all possible evolutionary histories for a given tumour sample.
The algorithm has been applied to a published study of clonal evolution
in relapsed AML [44] producing mostly consistent subclone structures.
The authors also present a de novo analysis of 15 matched primary-
relapse pairs from the TCGA ovarian cancer dataset and identify two
relapse patterns, which are underpinned by different order of clonal
selection.
4. Mutational timing across cancer types
Broadly, there are two primary ways to infer mutation timing in re-
lation to tumour evolution:
First, mutations and copy number events can be timed based on
population frequencies. This approach assumes that common pat-
terns can be identiﬁed in tumours from different patients [68,69]
and can be informed by analysis of pre-malignant stages. For exam-
ple, in Vogelstein and Fearon's seminal work a cross -section of
data types was used to infer that colorectal cancer can largely be ex-
plained as a linear chain of four genetic events [70]. An extension of
the linear view of tumour evolution is the oncogenetic tree approach,
which represents tumour evolution as a tree structure, permitting
diverging temporal ordering of events [71,72]. The tree structure
can be further relaxed using tumour progression models [60] per-
mitting insights into the order in which modiﬁcation in signalling
pathways occurs during tumourigenesis [73].
A second, alternative approach to infer mutation timing involves
utilising the heterogeneity observed within single tumours. Such an ap-
proach uses phylogenetic reconstruction to distinguish between truncal
events, occurring early in tumour evolution, and branched events,
which necessarily occur after tumorigenesis. By analysing single cases
this approach takes into account the variation in the evolution of indi-
vidual cancers, although ultimately the combination of both approaches
will gain maximal insights. In this section, we review the most up-to-
date evidence formutational timing using single tumour samples across
different cancer types.
The results are summarised in Fig. 3.
4.1. Haematological malignancies
To date, the most comprehensive studies of clonal architecture
have been applied to haematological malignancies. Compared to
solid malignancies, analyses of such data are less hampered by
extensive and varied stromal contamination. Haematological malig-
nancies are characterised by a low mutation burden. Whilst this fa-
cilitates driver event identiﬁcation it also means that fewer clonal
markers are available for the reconstruction of tumour history, espe-
cially if only coding regions are included. For this reason whole ge-
nome sequencing (WGS) is the preferred method in leukaemia
studies.
4.1.1. De novo and treatment-related acute myeloid leukaemia (AML)
Ding et al. [44] performed WGS of eight primary tumour/relapse
AML pairs. Two distinct patterns of evolution were described in these
AML
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Fig. 3. Summary of clonal and subclonal mutations in speciﬁc tumour types. Clonal mutations are shown on the trunk (blue) and subclonal on the branches (red). Mutations which have
been reported as both clonal and subclonal are indicated by an asterisk. Mutationswhich are predominantly clonal and infrequently detected as subclonal are shown in smaller font in the
tree branches. Copy number events are shown in italics. AML = acute myeloid leukaemia; MDS=myelodysplastic syndrome; CLL = chronic lymphocytic leukaemia; LUAD= lung ad-
enocarcinoma; ccRCC = clear cell renal cell carcinoma; GBM= gliobalstoma multiforme; CRC = colorectal cancer. The following studies are included in this data summary: Ding et al.
2012, Welch et al. 2012, Mazzarella et al. 2014, Klco et al. 2014, Walter et al. 2012, Wong et al. 201, Walter et al. 2012, Papaemmanuil et al. 2013, Landau et al. 2013, Schuh et al. 2012,
Melchor et al. 2014, Bohn et al. 2014, De Bruin et al. 2014, Zhang et al. 2014, Su et al. 2012, Van Allen et al. 2014, Ding et al. 2014, Gerlinger et al. 2012, Gerlinger et al. 2014, Voss et al.
2014, Sankin et al. 2014, Francis et al. 2014, Szerlip et al. 2012, Diaz et al. 2012, Brannon et al. 2014, Donna et al. 2014, Nik-Zainal et al. 2012, Ding et al. 2010, Shah et al. 2009, TCGA
2011, Bashashati et al. 201, Campbell et al. 2012, and Yachida et al. 2010.
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the relapse clone by gaining relapse-speciﬁc mutations, or, the more
common pattern, a late subclone in the primary was enriched in the re-
lapse sample. Mutations in DNMT3A, NPMP, TPRT, SMC3, WT1 RUNX1
and IDH2were present at diagnosis and relapse and contributed to the
founding clones, whilst mutations in FLT3, IDH1 and ETV6were consis-
tently subclonal. Otherwhole genome sequencing approaches to prima-
ry AML have identiﬁed exclusively clonal mutations in DNMT3A, NPM1,
IDH1 and SMC1A in a cohort of 24 cases, and predominantly subclonal
mutations in NRAS, FLT3, ETV6, EWSR1[74,75]. In a meta-analysis of
paired diagnosis-relapse samples which had been proﬁled by a variety
of methods [76] either loss or gain of mutations at relapse was notable
in FLT3, KIT, NRAS/KRAS, WT1 and IDH1/2 suggesting that these events
occur in subclones. Once more DNMT3A, TET2 and NMP1 were shown
to be clonal events.
In keeping with these studies Klco et al. [77] described subclonal
mutations in FLT3 and IDH1/2. This study also incorporated xenotrans-
plantation from unmanipulated tumour material. Different subclones
had varying engraftment potential, (no founding clones were observed
in the engrafting populations), but therewas nodirect relationshipwith
the evolutionary history of leukaemia in the patient.
AML can arise from a pre-existingmyelodysplastic syndrome (MDS)
(secondary AML) and also as a consequence of previous chemotherapy
(treatment-related AML). Walter et al. [78] reconstructed the clonal
architecture of progression from MDS to AML. All seven cases under
study conformed to the linear models of clonal evolution: MDS-
founding clone persisted in secondary AML and was carried forward
with each acquisition of new sets of mutations, resulting in an increas-
ing mutational burden. Mutations in TET2, IDH1/2, STAG2, TP53 andU2AF1 were observed in both sets of samples indicating that they are
early founding events in MDS. Mutations in WT1, PTPN11, RUNX1,
SMC3, FLT3, RAS and CEBPA were restricted to the transformed AML
sample suggesting they were later events. The same group conﬁrmed
their ﬁndings in an extension cohort of secondary AML cases [79].
Critically, in the latter study the authors compared the clonal architec-
ture deﬁned by WGS to that inferred from SNVs in 94 candidate genes
concluding that the VAFs of candidate genes did not fully recapitulate
the clonal architecture deﬁned by WGS.
Therapy-related AML is characterised by a higher frequency of TP53
mutations and resistance to chemotherapy. A recent study of therapy-
related AML andMDS [80] detected very low frequency TP53mutations
long before AML/MDS was diagnosed and in some cases before
chemotherapy was given, suggesting that TP53 mutations were not a
direct result of treatment. Further, TP53 mutations were detectable in
healthy volunteers of older age [80]. These ﬁndings support a model
in which rare haematopoietic progenitor cells harbour age-related
TP53mutationswhich are resistant to chemotherapy andwhich expand
preferentially following therapy. In two separate studies of WES of
peripheral blood cells involving over 30, 000 healthy individuals clonal
haematopoiesis was shown to increase with age [81,82]. Detectable
clonal expansions involved the known early driver events in AML:
DNMT3A, ASXL1, and TET2 and were associated with increased risk of
haematological cancers. In a subset of cases it was conﬁrmed that AML
arose from pre-existing clones [81]. Detection of these early events in
the blood of healthy individuals presents a potential cancer screening
opportunity.
Finally, a report of single cell sequencing from cases of MDS
progressing to secondary AML [63] validated the clonal architecture
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clonality of a few initially ambiguous mutations.
4.1.2. Chronic lymphocytic leukaemia (CLL)
Landau et al. [9] performed an integrated analysis of whole exome
sequencing and copy number variation in 149 cases of CLL. Using VAFs
they identiﬁed events that were predominantly clonal/early, including
MYD88, trisomy 12, and del 13q. Mutations in ATM, TP53 and SF3B1
were predominantly subclonal/late events. In a subset of patients they
obtained temporally separate samples and demonstrated that disease
progression coincided with the expansion of subclones containing
driver mutations. In keeping with this observation, independent of the
driver identity, subclonality of driver events was linked to adverse
clinical outcomes in CLL.
Schuh et al. [42] used whole genome sequencing to track clonal
architecture in three cases of CLL at ﬁve separate time points for up to
seven years. Subclonal populations were evident at all time points.
Clonal mutations were detected in genes recurrently mutated in CLL
including SF3B1, SAMHD1 and MED12. ATM, PLEKHG5, and IRF4 were
subclonal events. The patterns of progression varied in the three cases.
In one instance disease progression was linked to the expansion of a
subclone harbouring a mutation in MAP2K1 with ERK1/2 phosphoryla-
tion in lymphocytes mirroring the expansion. By contrast, in another
case the balance of subclonal and clonal populations remained steady
throughout the disease course suggesting that factors other than clonal
evolution drove disease progression in this instance.
4.1.3. Myelodysplastic syndrome (MDS)
Walter et al. [79] screened 94 candidates (recurrently mutated
genes) in a cohort of 150 cases of MDS. The range of VAFs was broad
in all cases with no genes exclusively mutated early or late. However,
they made several observations about mutational pairing. Mutations
within a gene group including spliceosome, transcription factor, activat-
ed signalling/RAS pathway and cohesion were largely mutually exclu-
sive. TP53mutations were stand-alone mutational events in two third
of the cases but they co-occurred with complex karyotype. They ob-
served co-occurrence of mutations in three pairs of genes, including
RUNX1 and STAG2, EZH2 and TET2, and BCOR and U2AF1 and a mutual
exclusivity between TP53 and spliceosome genes, andNRAS and cohesin
genes.
Papaemmanuil et al. [83] also applied a targeted approach sequenc-
ing 111 genes across 738 cases of MDS. They present strong evidence
that mutations in splicing factors including U2AF1, SF3B1 and U2AF1 as
well as those in DNA methylation genes (TET2, EZH2, ASXL1) occur
early in disease evolution, whilst mutations in kinases such as NRAS
and KIT are late events. In contrast to CLL, driver mutations had equiva-
lent prognostic signiﬁcance, whether clonal or subclonal, and survival
was linked to the overall number of drivermutations. Lastly, the authors
infer that early driver mutations can dictate the future trajectories of
disease evolution in MDS although longitudinal studies are required to
conﬁrm these ﬁndings [83].
4.1.4. Multiple myeloma (MM)
Several studies have reported whole genome [14,17], exome [15,16]
and single cell sequencing [84] of MM samples. The only consistently
early events are the characteristic translocations t(4;14), t(11:14) and
t(14;16). Mutations in BRAF and RASwere observed as both clonal and
subclonal, suggesting that these variants can contribute to tumour initi-
ation, maintenance or progression. Unusually, BRAF and RASmutations
co-occurred in some of the samples [14,17]. In some cases both variants
were present at a subclonal level and potentially drawn from different
subpopulations but in one case both BRAF and KRAS mutations were
found in the same (founding) clone. These observations are suggestive
of parallel evolution, which has been reported in other cancers [5],
highlighting the importance of the RAS-RAF pathway inMM. In keeping
with this notion, a recent report linked the evolution of a BRAFV600Esubclone as the mechanism of disease progression in a patient with
MM [85].
4.1.5. Follicular lymphoma (FL)
Using CD20 as the marker Green et al. [86] sorted FL cells from 8
cases (including two matched FL-relapsed FL pairs). IGH-BCL2 trans-
location and CREBBP mutations were clonal and maintained between
diagnosis and relapse. Mutations inMLL2 and TNFRSF14were subclonal
and lost at relapse in one case. Interestingly, MLL2 is highly mutated in
FL and this has been taken as evidence that it is also an early event. The
ﬁndings in this study caution against using mutational frequency as a
surrogate for clonality. Bodor et al. [87] analysed 101 EZH2-mutated
cases of FL including 33 paired diagnosis-relapse samples and showed
that EZH2 mutations are predominantly clonal events. Okosun et al.
[88] performed WES or WGS on ten cases of FL-transformed FL pairs,
and reported clonally dominant mutations in CREBBP, EZH2, STAT6, but
alsoMLL2 and TNFRSF14, which were reported as subclonal in a previ-
ous study [86]. Mutations in MYD88 and TNFAIP3 were restricted to
the transformation biopsy indicating that they are late events.
4.2. Solid malignancies
4.2.1. Lung adenocarcinoma (LUAD)
With respect to EGFR genotype both intratumour heterogeneity [89]
and discordance in primary-metastasis pairs [90] have been reported in
LUAD with only one study contradicting these ﬁndings [91]. These
observations are in keeping with varied and mixed responses to EGFR
inhibitors in EGFR-mutant LUADs. Further, variants associated with
secondary resistance to EGFR inhibiton such as EGFRT790M and MET
ampliﬁcation are found in the subclones of the pretreatment tumour
[21,92,93]. By contrast, secondary mutations in ALK which drive resis-
tance to ALK inhibitors in ALK-rearranged tumours appear to arise de
novo in progressing tumours [92].
On genome and exome-wide scale two recent studies have reported
multi-region sequencing of primary Stage I–III LUAD tumours. Zhang
et al. [10] applied multi-region whole-exome sequencing (WES) to 11
cases. They reveal evidence of ITH in all the cases but ﬁnd that majority
of mutations are ubiquitous. However, as LUADs are characterised by
tobacco-induced high mutational burden, majority of clonal mutations
are likely to be passengers acquired prior to malignant transformation.
The size of the subclonal fraction correlated with patients' outcome in
this small data set. Mutations in known cancer genes were early events
(SETD2, KRAS, BRCA1, EGFR, ARID1B, PITCH1, ARID1A and STK11) with the
exception of a mutation in ATRX, which was subclonal in one case. We
[27] proﬁled multiple regions of seven cases of operable LUAD using a
combination of WES andWGS. We too demonstrate that known driver
events occur early in the course of lung carcinogenesis (EGFR, RB1, TP53,
NF1, SETD2, PTEN). Mutations in PIK3CA, TGFBR1 and PTPRD were
subclonal/late events, whilst activating mutations in BRAFwere report-
ed as both clonal and subclonal. Compared to ccRCC tumours, LUADs ap-
pear to have less ITH, however there are important caveats to be
considered in the comparison of these studies. First is that the LUAD co-
horts [10,27] included earlier stage tumours than the ccRCC cohort [5],
second, as alluded to above, many of the truncal events will have oc-
curred pre-transformation and third, approaches to identifying driver
events are based on overall mutational frequencies and by deﬁnition
may omit drivers which are consistently subclonal.
4.2.2. Melanoma
Most sequencing studies, including the TCGA cohort, consist of
metastatic melanoma tissue. Melanoma primary lesions are small and
usually required in their entirety for histological analysis. In this respect,
phylogenetic studies have been limited, but not uninformative. Ding
et al. [26] inferred clonal structures from a combination of whole
genome sequencing and targeted re-sequencing of 124 cases ofmelano-
ma. Applying SciClone to deeply sequenced calls they clustered
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tional burden and complex copy number landscape in melanoma the
boundaries of some clusters were difﬁcult to establish [26]. They observe
that activatingmutations in BRAF and NRAS are consistently early events
in melanoma. This is congruous with their role in melanomagenesis:
both BRAF[94] and NRAS[95] mutations are found in acquired naevi,
which are precursors to melanoma. However, more recent studies
challenge the notion that they are exclusively founder/clonal events.
Lin et al. [96] isolated and sequenced single melanoma cells from prima-
rymelanomas and found they contained both BRAF-wild-type and BRAF-
mutant tumour cells, observing that BRAF-mutant subclones were al-
ways selected during progression. Several groups have reported co-
existing NRAS and BRAF mutant subclones within the same primary
[97] or metastatic lesions [98]. This is at odds with the long-held view
of their mutual exclusivity [99]. These recent ﬁnding illustrate that
both BRAF and NRASmutations can be subclonal/late events in melano-
ma which has special relevance for mechanisms of progression on
BRAF inhibitors [100]. In patients with co-existent BRAF and RASmuta-
tion BRAF inhibitors can have paradoxical, tumour-enhancing effects.
With the exception ofMEK1mutations [100,101] components of the
MAPK pathway are predominantly early events. It is known that loss of
tumour suppressor genes including PTEN, CDKN2A and TP53, or cell-
cycle regulation genes such as CCND1 and CDK4[102] are needed forma-
lignant transformation of BRAF mutant naevi. Therefore mutations in
these gens occur after BRAFmutations although their exact timing is un-
clear. It is likely thatmutations inCDKN2A and TP53occur early on,whilst
components of the PI3K–AKT pathwaywere found to be both clonal and
subclonal, and mutations in MUC2, PCMDT1, CTNNB1, and ARID2 were
mostly subclonal [103]. Subclonal expansion is linked to BRAF inhibitor
resistance in BRAF-mutant melanomas [101], however resistance can
also be mediated multiple clonal events in the RAS–RAF and the PI3K–
AKT pathways.
4.2.3. Clear cell renal cell carcinoma (ccRCC)
Multi-region sequencing of 10 ccRCCs revealed that mutations in the
von Hippel–Lindau (VHL) gene, together with the loss of chromosome
3p, are obligatory early events in this cancer type [5]whilst mutations
in PBRM1 could be either clonal and subclonal. However, mutations in
TP53, SETD2, BAP1, PTEN, mTOR, PIK3CA and KDM5C were only ever
found to be subclonal, suggesting that they occur later in tumour evolu-
tion. Preclinical studies have shown that BAP1 cooperateswithVHL to in-
duce ccRCC [104]. Another sequencing study focused on proﬁling ﬁve
genes through multi-regional sequencing of ccRCC tumours [105]. In
this case VHL mutations were consistently clonal, PBRM1 was clonal in
60/% of cases and SETD2 and BAP1 in a third of cases and KDM5C in
b25% of cases. This study sampled a maximum of four regions per
tumour and under sampling may have given the illusion of clonality
with respect to BAP1, SETD2 and KDM5C. A further study [106] examined
up to four regions of primary ccRCC tumours and demonstrated clonal
mutations in TP53 and PBRM1 and subclonal mutations in BAP1. Both
clonal and subconal mutations were detected in TSC1 and mTOR and
their presence was linked to extended beneﬁt from mTOR inhibitors.
As we found that SETD2 mutations were a later event occurring in the
proximal branches of the tumour phylogenetic trees [5]wehypothesised
that SETD2 loss of functionmight drive ITH. Silencing SETD2 led to defec-
tive homologous recombination repair, DNA replication stress and im-
paired localisation of DNA polymerase delta to chromatin. Consistent
with these observations, we found that breakpoint regions in SETD2mu-
tant tumours are localised towards H3K36 sites that are normally
trimethylated by SETD2. These data suggest that mutational timing can
be used to infer novel drivers of branched evolution [107].
4.2.4. Glioblastoma multiforme (GBM)
GBM is an aggressive primary brain malignancy associated with ex-
tremely poor prognosis and limited response to systemic therapies.
GBM samples are characterised by marked ITH with evidence ofactivation of multiple receptor tyrosine kinases within a single tumour
[108,109]. However, due to sampling difﬁculties, detailed studies of
clonal evolution in GBM have been limited. Tumours are often resected
in a piecemeal fashion, which distorts their architecture, and compro-
mises spatial sampling. Opportunities for temporal sampling are infre-
quent, as following primary resection majority of patients do not
undergo repeat surgery. Sottoriva et al. [32] deployed an especially de-
signed method to multi-region sample 11 cases of GBM. Each case
displayed speciﬁc patterns of evolution, but overall, copy number alter-
ations in EGFR, CDKN2A/B/p14ARF,MET and NF1were identiﬁed as early
events, and aberrations in PDGFRA, PTEN, MDM4, and AKT3 as late
events.
Using a combination of single cell and bulk sequencing, Francis et al.
[110] demonstrated that following EGFR ampliﬁcation, parallel evolu-
tion involves multiple distinct EGFR variants. Study authors propose
two models of clonal diversiﬁcation in GBM: one in which common
clonal mutations are followed by divergence of RTK genotype (e.g.
EGFR, PDGFR and MET) [109] and the other where evolution is
underpinned by the emergence of multiple variants of a single RTK
(e.g. EGFR) [23,110].
4.2.5. Colorectal cancer (CRC)
The established model of colorectal tumourigenesis proceeds
through a linear evolution starting with an inactivating mutation in
APC, followed by activating mutations in KRAS/BRAF, and subsequent
waves of clonal expansion driven by mutations in TGFB, PIK3CA and
TP53[111]. This model is largely supported by genomic studies to date.
Driver mutations in KRAS, NRAS and BRAF are concordant in primary-
metastasis studies, implying that they are early events which persist
throughout the disease course [112]. Recently, ultra-deep sequencing
of 15 matched synchronous primary-metastasis pairs conﬁrmed
concordance with respect to PIK3CA and TP53 genotypes [113]. Other
studies have conﬁrmed limited variation in primary-metastasis or
inter-metastases comparisons [35,36]. One study reported several de
novo alterations in the metastases, including potentially deleterious
mutations in FBXW7, DCLK1 and FAT2[35]. Genomic proﬁling of individ-
ual glands and single cells from 15 cases of CRC conﬁrmed that muta-
tions in APC, KRAS PIK3CA and TP53 were early events [4].
Patients with metastatic CRC whose tumours are conﬁrmed to be
RAS wild-type (WT) are often treated with EGFR inhibitors. Following
an initial response, patients invariable develop resistance to anti-EGFR
therapy. In a study reported by Diaz et al. [114] almost 40% of patients
with KRAS WT tumours treated with panitumumab, an EGFR inhibitor
had KRAS mutations detectable in the circulating tumour DNA at the
time of progression. Multiple distinct KRAS mutations were evident in
three cases. Mathematical modelling performed in this study indicates
that KRASmutations were present in subclones prior to panitumumab
treatment. Although this hypothesis was not conﬁrmed by sequencing
of pre-treatment tumours, it is in keepingwith what has been observed
in other cancers. Thus, it appears that KRASmutations can also be late
events in CRC and that in this capacity they drive acquired resistance
to EGFR blockade.
4.2.6. Breast cancer
Several analyses of paired samples have reported on clonal evolution
in breast cancer. Shah et al. [41] performed whole genome sequencing
of a metastatic sample followed by proﬁling of select variants in the
primary tumour, which was removed 9 years previously. 19 mutations
were exclusive to the metastasis, suggesting they had arisen de novo.
Mutations in ABCB11, HAUS3, SLC24A4, SNX4 and PALB2 were detected
in the primary tumourwith VAFs comparable to those in themetastasis,
whilst mutations in KIF1C, USP28, MYH8, MORC1, KIAA1468 and
RNASEH2A were enriched in the metastasis. Ding et al. [24] reported
whole exome sequencing of a trio of a primary breast tumour, brain
metastasis and a xenograft derived from the primary tumour. Clonal
mutations in JAK2 andCSMD1had comparable VAFs in all three samples,
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in the metastasis. With the exception of a TP53 mutation (which was
only enriched in the xenograft), the mutation enrichment pattern in
the xenograft mirrored that in the metastasis.
Nik-Zainal et al. [61] used a novel algorithm [115] to reconstruct the
genomic history of 21 breast cancers. Multiple subclonal populations
were detected with a dominant subclone evident in all cases. Mutations
in TP53, PIK3CA and ERBB2, MYC and CCND1 ampliﬁcation, gains in 1q
and 8q and losses of 17p were clonal, with subsequent divergence
among subclones mostly evident in large scale chromosomal events.
Wang et al. [50] performed WGS/WES on ~50 single nuclei isolated
from two cases of oestrogen-receptor positive breast cancer (ERBC) and
triple-negative breast cancer (TNBC), respectively. Increased sampling
led to detection of additional subclonal variants, but overall, TNBC was
characterised by a greater extent of clonal diversity. They detected clon-
al mutations in known cancer genes including PIK3CA, CASP3 and FBN2,
and subclonal mutations in TGFB2, CHRM5, AURKA, SYNE2 and PP2R1.
4.2.7. Ovarian cancer
TCGA analysis of ovarian carcinoma demonstrated that TP53muta-
tions are present in almost all cases indicating their role as an early
event in these tumours. Most other mutations were low frequency
events mutated in b5% of all cases [116]. Bashshati et al. [40] performed
a combined genomic analysis of six cases with multiple temporally and
spatially separate samples revealing profoundly divergent mutational
proﬁles and unique evolutionary trajectories in each case. TP53muta-
tions were conﬁrmed as consistently early/clonal events, but mutations
in other driver genes, including, PDGFRB, PIK3CA and CNTNB1 and NF1
were mostly subclonal.
4.2.8. Pancreatic cancer
Two studies included 7 matched primary and metastases pairs and
showed that mutations in KRAS, CDKN2A, TP53 and SMAD4were consis-
tently early events [25,28]. Many mutations across the 7 cases were
subclonal, but there was only one recurrent subclonal event, a mutation
in OVCH1, reported in two patients. Based on functionality, private
mutations in CNTN5, DOCK2, MEPIA and LMTK2 could be contributing
to the metastatic process in these cases [28]. Data from these studies
indicates ongoing evolution in the metastatic sites, suggesting that the
repertoire of mutations required for metastatic progression is not fully
contained in the primary tumour. Additionally, Campbell et al. show
that phylogenetic trees across spatially separate metastases show
organ-speciﬁc branches [25].
5. Conclusions
Mutations that occur early on in the disease course may be ideal
therapeutic targets, whilst mutations that occur later are linked to dis-
ease progression and treatment resistance.Most studies to date have in-
ferredmutational timing from single samples frommultiple individuals.
Current computational methods will require ongoing reﬁnement in
order to deal with the limitations of bulk unpaired-sample sequencing.
Paired sampling offers an improved resolution of mutational timing.
Formalised longitudinal studies such as TRACERx [117] will attempt to
map cancer's spatiotemporal diversity in great detail. Testing of
in vitro and in vivo models derived from (multi)sampled tumours can
be integrated with the genomic data to present functionally relevant
subclonal dynamics. Ultimately, single cell sequencing will provide the
most precise estimates of chronology of mutational events, but these
techniques are far from widely accessible at this stage. Where tissue
sampling is not practical circulating tumour DNA (ctDNA) can be used
as a surrogate for tumour tissue. However, it remains to be seen wheth-
er analyses of ctDNA can fully recapitulate the diversity of the primary
or metastatic tumours.
There is a striking variability within and across tumour types as to
the timing of different mutations. At this stage, VHL mutations andloss of 3p in ccRCC and APC mutations in CRC appear to be the only
obligatory truncal events. TP53 shows ﬁdelity within tumour types
(early in ovarian cancer and late in ccRCC) but it is promiscuous from
one cancer to the next. This may reﬂect its role in a diverse range of cel-
lular processes, potentially as both a tumour suppressor and an onco-
gene, or even the underlying mutational processes: mutagen-induced
TP53 mutations are frequently early events [118]. BRAFmutations are
associated with many malignancies but their founder mutation status
appears to be limited to melanoma. Considering the evidence to date,
a distinction emerges between haematological and solid malignancies.
Mutations in RTKs are frequently early mutations in solid tumours
whilst in leukaemia and multiple myeloma they are predominantly
late events. These patterns could be the result of the different microen-
vironments, or the spatial constraints in solid tumours [119]. Thus,
although the same genes can be altered in many different tumour
types, the relative timing of their disruption with respect to tumour
evolution is varied, indicating the importance of tissue context.
The ability to estimate mutational timing presents both prognostic
and therapeutic opportunities. It is likely that mutational timing when
combined with an analysis of distinct genomic instability patterns will
generate biological opportunities to decipher drivers of branched evolu-
tion itself. Efforts to decipher “evolutionary rule books” across cancer
types may support drug development and clinical trial design as well
as inform drug discovery approaches to limit cancer diversity.
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